BCHT

Changchun BCHT Biotechnology Co. (hereinafter referred to as “BCHT” or “the company”) is an innovative biopharmaceutical enterprise committed to the prevention and control of infectious diseases. Since its establishment in 2004, BCHT has been engaged in research and development, manufacturing and distribution of vaccines for human use. Through years of development, BCHT has gradually established a complete operation system around core products and implemented quality management in the whole life cycle of products. BCHT now has its own vaccine manufacturing base which cover 225,700 square meters in total. In June 2021, the company made its initial public offering and was successfully listed on the Science and Technology Innovation Board.

The company’s independent intellectual property product, Varicella Vaccine, Live was successfully marketed in 2008. It is the first varicella vaccine to remove animal-derived gelatin from adjuvant in China, which greatly reduces the incidence of adverse reactions. It is the first varicella vaccine with a validity period of 36 months in the world and its stability is the best among similar products. The market share has been the first in China for many years.

Influenza Vaccine, Live, Nasal, Freeze-dried launched in 2020 is a cooperative project with World Health Organization, which has been included in WHO Global Action Plan for Influenza Vaccines and is the exclusive LAIV in China. This vaccine can be mass produced in a short time, which is conducive to expanding market share. Its nasal spray administration is easy to use, and its good compliance will benefit in mass immunization, which is very important for influenza prevention and control in China. In 2025, its liquid dosage form was launched.

Herpes Zoster Vaccine, Live produced by BCHT was approved for marketing in January 2023 which is the world's first Herpes Zoster Vaccine, Live for people aged at or above 40 years old, it fills the gap in domestic herpes zoster vaccines market, providing a new preventive measure for more eligible.

As a fast-growing enterprise, BCHT aims to exploring international market and business opportunities. Since 2009, BCHT has started to export its products. Until now, BCHT has successively established trade cooperation with India, Indonesia, Pakistan, Nigeria, Bangladesh, Ghana, etc. Its international business has expanded to 17 countries across 4 continents, with vaccine exports exceeding 5 million doses.